Archive · 11 Jun 2025
OneSource, Xbrane Partner on Biosimilars Manufacturing
Two companies, OneSource and Xbrane, are teaming up to manufacture copies of existing medicines, called biosimilars.
OneSource will make these medicines in a large facility in India.
Xbrane's lead product, Ximluci, is available in Europe and is seeking approval in the US.
This collaboration will help Xbrane distribute their medicines worldwide more easily.
It should also help make medicines more accessible and affordable.
OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing.
The partnership aims to commercialize Xbrane's biosimilar portfolio.
Xbrane's lead candidate, Ximluci, is approved in Europe and awaiting US approval.
OneSource will receive a tech-transfer for commercial product manufacturing in Bengaluru.
The collaboration seeks to strengthen Xbrane's supply chain.
- Who
- OneSource Specialty Pharma, Xbrane Biopharma, Neeraj Sharma, and Martin Åmark.
- What
- OneSource Specialty Pharma and Xbrane Biopharma are partnering for the commercial manufacturing of Xbrane's biosimilar portfolio.
- When
- Published on June 11, 2025. The partnership is currently ongoing.
- Where
- OneSource's facility in Bengaluru, India.
- Why
- To strengthen Xbrane’s global supply chain and provide affordable medicines to patients.
- Partners
- OneSource Specialty Pharma, Xbrane Biopharma
- Focus
- Biosimilar Manufacturing
- Lead Candidate
- Ximluci (ranibizumab biosimilar)
- Ximluci Approval Status
- Approved in Europe, Under Review in US
- Location
- Bengaluru, India (OneSource facility)
- Estimated Peak Sales
- €23 billion (for biosimilar portfolio)